by The global Gastric Motility Disorder Drug Market is estimated to be valued at US$ 57.65 Bn in 2024 and is expected to exhibit a CAGR of 5.4% over the forecast period from 2024 to 2031. Gastric motility disorder involves disruption or slowness in movement of content through the stomach leading to gastric dysfunction. Some common gastric motility disorders includes gastroparesis, gastric stasis, gastric stasis, and chronic intestinal pseudo-obstruction etc. Drugs used in treatment of gastric motility disorders helps in increasing stomach motility by boosting smooth muscle contractions. Some common drug classes used are prokinetics, antiemetics, antidepressants, Botox injections and gastric pacemakers etc. The gastric motility disorder drug market is witnessing significant growth with increasing prevalence of gastrointestinal disorders, diabetes and growing R&D investment in drug development.
Key Takeaways
Key players operating in the Gastric Motility Disorder Drug Market size are Pfizer Inc., Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Boehringer Ingelheim, Eli Lilly and Company, Bristol Myers Squibb, Daiichi Sankyo Company, Limited, Bausch Health Companies, Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals, Eisai Co., Ltd., Ferring Pharmaceuticals, UCB, Evoke Pharma, and Cadila Pharmaceuticals.
Key players are focused on developing innovative drugs and combination therapies to increase effectiveness. For instance, in 2021, Evoke Pharma received FDA approval for Gimoti for treatment of diabetes induced gastroparesis.
The growing prevalence of gastroparesis, obesity and other gastrointestinal disorders is majorly driving the demand in gastric motility disorder drugs market globally. According to a study, gastroparesis affects over 6 million Americans alone.
Key players are also expanding their production capabilities and global presence through acquisition and partnership strategies to cater to demand from emerging markets like Asia Pacific and Latin America. For instance, in 2021 Takeda acquired GammaDelta Therapeutics to expand its pipeline of gastro-intestinal focused therapies.
Market Key Trends
Development of novel drug delivery technologies to improve bioavailability and efficacy is a key trend witnessed in the gastric motility disorder drug market. These includes use of polymers, microneedles, nanoparticles and liposomes for controlled and targeted drug release in stomach. Some other emerging trends includes use of gastric pacemakers, botulinum toxin injections and stem cell therapies for gastroparesis treatment. Companies are also focusing on development of combination drug formulations having prokinetics coupled with antiemetics or antidepressants to increase treatment effectiveness.
Porter’s Analysis
Threat of new entrants: New companies may find it difficult to enter this market due to high costs involved in R&D activities and clinical trials.
Bargaining power of buyers: Large patient population suffering from gastric motility disorder puts less bargaining power in buyers’ hands.
Bargaining power of suppliers: Established key players dominate the supply side giving them a stronger position in negotiations.
Threat of new substitutes: Limited substitute options currently exist for prescribed drugs in this category.
Competitive rivalry: Intense competition exists between major pharmaceutical manufacturers to gain higher market share.
Geographical Regions
North America region currently holds the major share of the gastric motility Gastric Motility Disorder Drug Market Regional Analysis value owing to established healthcare infrastructure and raised awareness levels.
Asia Pacific region is poised to witness the fastest growth during the forecast period due to the rising gastric disease prevalence coupled with growing medical tourism across India and China.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
